Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients.

Author: EngelhornTobias, FröhlichKilian, HilzMax-Josef, HuhnKonstantin, LeeDe-Hyung, LinkerRalf A, NickelFlorian T, ProcklVictoria, UtzKathrin S

Paper Details 
Original Abstract of the Article :
Pivotal trials showed good clinical efficiency of the monoclonal antibody ocrelizumab while being well tolerated and manageable in multiple sclerosis (MS). However, data on adverse events in everyday practice are scarce. Hence, our study aims at investigating short-term tolerability of ocrelizumab i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.jns.2020.116973

データ提供:米国国立医学図書館(NLM)

Ocrelizumab in Multiple Sclerosis: Real-World Application

The vast desert of multiple sclerosis research is constantly evolving, seeking new and effective treatments to manage this debilitating disease. This study delves into the real-world application of ocrelizumab, a monoclonal antibody that has shown promising results in clinical trials. The researchers sought to investigate the short-term tolerability of ocrelizumab in a real-world setting, moving beyond the controlled environment of clinical trials.

While previous clinical trials demonstrated ocrelizumab's efficacy and safety in treating MS, this study aims to provide a more realistic view of its tolerability in everyday clinical practice. It analyzed data from a single center on 128 patients treated with ocrelizumab, offering valuable insights into the drug's performance in a non-ideal setting.

A Glimpse Into Real-World Tolerability

The study's focus on real-world application is crucial, as it helps bridge the gap between clinical trials and actual patient experiences. By examining the tolerability of ocrelizumab in a real-world setting, the researchers provide valuable data for clinicians and patients, informing their decision-making processes.

Navigating Multiple Sclerosis Treatment

Understanding the tolerability of a treatment is essential, especially for chronic conditions like MS, where patients often face long-term management. This research provides valuable insights for both patients and physicians, helping them navigate the complex world of MS treatment with greater confidence.

Dr.Camel's Conclusion

This study provides important insights into the real-world tolerability of ocrelizumab, a monoclonal antibody used to treat multiple sclerosis. By extending beyond the controlled environment of clinical trials, the researchers offer valuable data for clinicians and patients, informing their decision-making processes about this promising treatment option. The study underscores the importance of understanding the real-world application of treatments, as this provides a more realistic picture of their effectiveness and safety.

Date :
  1. Date Completed 2021-05-14
  2. Date Revised 2021-05-14
Further Info :

Pubmed ID

32563101

DOI: Digital Object Identifier

10.1016/j.jns.2020.116973

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.